Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GARY N GROSS

Allopathic & Osteopathic Physicians Allergy & Immunology Allergy

NPI
1285601336
CMS profile
58380
Location
DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$69,757.91

160 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 160 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GARY N GROSS

NPI 1285601336 · CMS profile ID 58380

Allopathic & Osteopathic Physicians / Allergy & Immunology / Allergy

DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 160 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1285601336?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GARY N GROSS, NPI 1285601336, CMS profile ID 58380. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 160 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1285601336?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). GARY N GROSS, NPI 1285601336, CMS profile ID 58380. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 160 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1285601336?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
GARY N GROSS, NPI 1285601336, CMS profile ID 58380, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 160 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1285601336?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

160 matching records · $69,757.91 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 160 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 160.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Teva Pharmaceuticals USA, Inc. $21.9206/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839565823 CMS
GlaxoSmithKline, LLC. $8.5806/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803043593 CMS
AstraZeneca Pharmaceuticals LP $17.3206/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834341491 CMS
Teva Pharmaceuticals USA, Inc. $1,680.0006/23/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839566033 CMS
GlaxoSmithKline, LLC. $13.7706/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802776803 CMS
AstraZeneca Pharmaceuticals LP $4,833.0006/14/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834349913 CMS
kaleo, Inc. $19.0906/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832119135 CMS
Covis Pharma GmBH $20.5606/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 844398313 CMS
Covis Pharma GmBH $20.5606/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 847691837 CMS
AstraZeneca Pharmaceuticals LP $94.5006/03/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834322601 CMS
AstraZeneca Pharmaceuticals LP $49.6106/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834328395 CMS
AstraZeneca Pharmaceuticals LP $11.2706/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834334647 CMS
AstraZeneca Pharmaceuticals LP $81.1706/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834345385 CMS
AstraZeneca Pharmaceuticals LP $11.2706/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834347617 CMS
SANOFI-AVENTIS U.S. LLC $73.7006/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843399253 CMS
AstraZeneca Pharmaceuticals LP $65.0006/02/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834339777 CMS
AstraZeneca Pharmaceuticals LP $361.6006/02/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834348837 CMS
AstraZeneca Pharmaceuticals LP $2.1605/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834325475 CMS
AstraZeneca Pharmaceuticals LP $11.5105/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834352361 CMS
USWM, LLC $14.7305/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834099321 CMS
AstraZeneca Pharmaceuticals LP $12.8505/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834331775 CMS
BioCryst US Sales Co., LLC $19.1105/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849111341 CMS
Optinose US, Inc. $1,100.0005/20/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851661859 CMS
GlaxoSmithKline, LLC. $13.8305/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801928333 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $21.4105/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763694362 CMS
Optinose US, Inc. $1,100.0005/13/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851661857 CMS
Regeneron Healthcare Solutions, Inc. $17.2905/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809583161 CMS
Teva Pharmaceuticals USA, Inc. $24.2805/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839565819 CMS
Covis Pharma GmBH $18.9405/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 847691817 CMS
Grifols USA, LLC $17.5004/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 846760563 CMS
AstraZeneca Pharmaceuticals LP $16.0304/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834353013 CMS
ALK-Abello, Inc $20.4604/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809205363 CMS
ALK-Abello, Inc $50.5004/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809205367 CMS
SANOFI-AVENTIS U.S. LLC $76.0704/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843399249 CMS
GENZYME CORPORATION $20.8704/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843399233 CMS
ALK-Abello, Inc $2.1004/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809205351 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.0004/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819952923 CMS
PFIZER INC. $19.4504/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832858177 CMS
GlaxoSmithKline, LLC. $16.2704/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802582411 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $21.0003/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763694364 CMS
AstraZeneca Pharmaceuticals LP $12.5003/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834354423 CMS
Pharming Healthcare, Inc. $21.7003/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820555739 CMS
AstraZeneca Pharmaceuticals LP $14.3903/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834342285 CMS
Grifols USA, LLC $14.5703/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 846750883 CMS
Regeneron Healthcare Solutions, Inc. $18.7203/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809583159 CMS
Teva Pharmaceuticals USA, Inc. $21.0603/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839565817 CMS
Optinose US, Inc. $2,000.0003/04/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851661953 CMS
Octapharma USA, Inc. $55.6603/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812974223 CMS
AstraZeneca Pharmaceuticals LP $13.6202/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834320961 CMS
GENZYME CORPORATION $18.4002/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843399207 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $73,602.40 168
PY2020 $25,023.61 99
PY2021 $69,757.91 160
PY2022 $81,721.37 154
PY2023 $99,086.59 179
PY2024 $139,366.92 187
PY2025 $113,659.13 215

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $790,709.03 73
PY2024 Principal investigator $694,057.65 62
PY2023 Recipient $2,209.93 5
PY2023 Principal investigator $223,012.98 15
PY2022 Principal investigator $129,662.42 37
PY2021 Recipient $750.00 2
PY2021 Principal investigator $360,964.12 90
PY2020 Recipient $2,046.62 11
PY2020 Principal investigator $315,126.28 75
PY2019 Recipient $530.00 1
PY2019 Principal investigator $601,354.76 68

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

73 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GlaxoSmithKline, LLC. $72.63 12/23/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192115148
Principal investigator 1 GlaxoSmithKline, LLC. $19,880.05 12/23/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192175583
Principal investigator 1 GlaxoSmithKline, LLC. $2,036.70 12/19/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192115140
Principal investigator 1 SANOFI US SERVICES INC. $12,552.00 12/08/2025 Non-covered Recipient Entity
Pharmaceutical Research Consulting Inc
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226087160
Principal investigator 1 SANOFI US SERVICES INC. $40.00 12/08/2025 Non-covered Recipient Entity
Pharmaceutical Research Consulting Inc
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226087163
Principal investigator 1 SANOFI US SERVICES INC. $80.00 12/08/2025 Non-covered Recipient Entity
Pharmaceutical Research Consulting Inc
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226087167
Principal investigator 1 GlaxoSmithKline, LLC. $24,148.80 11/25/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192115123
Principal investigator 1 GlaxoSmithKline, LLC. $25,237.80 11/25/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192115135
Principal investigator 1 SANOFI US SERVICES INC. $40.00 10/20/2025 Non-covered Recipient Entity
Pharmaceutical Research Consulting Inc
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226087152
Principal investigator 1 SANOFI US SERVICES INC. $4,874.00 10/20/2025 Non-covered Recipient Entity
Pharmaceutical Research Consulting Inc
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226087155
Principal investigator 1 GlaxoSmithKline, LLC. $4,765.50 10/17/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192173673
Principal investigator 1 GlaxoSmithKline, LLC. $3,041.10 10/17/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192175570
Principal investigator 1 Novartis Pharmaceuticals Corporation $620.78 10/08/2025 Non-covered Recipient Entity
THE PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190313167
Principal investigator 1 SANOFI US SERVICES INC. $40.00 10/06/2025 Non-covered Recipient Entity
Pharmaceutical Research Consulting Inc
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226087147
Principal investigator 1 GlaxoSmithKline, LLC. $7,288.20 10/02/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192175587
Principal investigator 1 GlaxoSmithKline, LLC. $7,830.90 10/02/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192175597
Principal investigator 1 SANOFI US SERVICES INC. $7,759.00 09/22/2025 Non-covered Recipient Entity
Pharmaceutical Research Consulting Inc
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226087141
Principal investigator 1 Genentech, Inc. $933.70 09/10/2025 Non-covered Recipient Entity
PHARMACEUTICAL RESEARCH AND CONSULTING INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211637610
Principal investigator 1 Genentech, Inc. $586.90 09/10/2025 Non-covered Recipient Entity
PHARMACEUTICAL RESEARCH AND CONSULTING INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211637618
Principal investigator 1 Genentech, Inc. $29.35 09/10/2025 Non-covered Recipient Entity
PHARMACEUTICAL RESEARCH AND CONSULTING INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211637627
Principal investigator 1 Genentech, Inc. $46.69 09/10/2025 Non-covered Recipient Entity
PHARMACEUTICAL RESEARCH AND CONSULTING INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211637631
Principal investigator 1 GlaxoSmithKline, LLC. $1,184.00 09/08/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192173662
Principal investigator 1 GlaxoSmithKline, LLC. $8,817.30 09/03/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192173682
Principal investigator 1 GlaxoSmithKline, LLC. $4,833.90 09/03/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192173686
Principal investigator 1 SANOFI US SERVICES INC. $2,400.00 09/03/2025 Non-covered Recipient Entity
Pharmaceutical Research Consulting Inc
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226087136
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,409.28 08/28/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK
ALTA - Albuterol budesonide Treatment in Acute airway obstruction his is a multi-center randomized double-blind 2-period cross-over study evaluating efficacy and safety of repeated doses of PT027 albuterol budesonide pressurized metered dose inhaler pMDI compared to PT007 albuterol pMDI in participants with asthma and acute airway obstruction induced by 2 mannitol challenges 7 hours apart No dispute reported 06/30/2026 1185549141
Principal investigator 1 Genentech, Inc. $19,261.00 08/20/2025 Non-covered Recipient Entity
PHARMACEUTICAL RESEARCH AND CONSULTING INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211637623
Principal investigator 1 SANOFI US SERVICES INC. $19,869.00 08/18/2025 Non-covered Recipient Entity
Pharmaceutical Research Consulting Inc
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226087132
Principal investigator 1 GlaxoSmithKline, LLC. $31,886.10 08/13/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192175592
Principal investigator 1 Genentech, Inc. $1,500.00 08/06/2025 Non-covered Recipient Entity
PHARMACEUTICAL RESEARCH AND CONSULTING INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211637605
Principal investigator 1 Genentech, Inc. $1,500.00 08/06/2025 Non-covered Recipient Entity
PHARMACEUTICAL RESEARCH AND CONSULTING INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211637614
Principal investigator 1 GlaxoSmithKline, LLC. $2,340.00 08/06/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192175579
Principal investigator 1 GlaxoSmithKline, LLC. $2,369.70 08/04/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192175566
Principal investigator 1 GlaxoSmithKline, LLC. $11,688.60 07/23/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192173670
Principal investigator 1 GlaxoSmithKline, LLC. $12,675.00 07/21/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192173678
Principal investigator 1 SANOFI US SERVICES INC. $2,737.00 07/21/2025 Non-covered Recipient Entity
Pharmaceutical Research Consulting Inc
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226087129
Principal investigator 1 SANOFI US SERVICES INC. $20,469.00 07/02/2025 Non-covered Recipient Entity
Pharmaceutical Research Consulting Inc
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226087121
Principal investigator 1 SANOFI US SERVICES INC. $2,400.00 07/02/2025 Non-covered Recipient Entity
Pharmaceutical Research Consulting Inc
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226087125
Principal investigator 1 GlaxoSmithKline, LLC. $6,721.20 06/20/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192115115
Principal investigator 1 GlaxoSmithKline, LLC. $111.10 06/02/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192115155
Principal investigator 1 GlaxoSmithKline, LLC. $5,205.60 05/21/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192173690
Principal investigator 1 SANOFI US SERVICES INC. $11,200.00 05/12/2025 Non-covered Recipient Entity
Pharmaceutical Research Consulting Inc
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226087117
Principal investigator 1 AstraZeneca Pharmaceuticals LP $98,710.91 05/08/2025 Non-covered Recipient Entity
PHARMACEUTICALS RESEARCH CONSULTING INC.
A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma No dispute reported 06/30/2026 1185549147
Principal investigator 1 Genentech, Inc. $518.00 05/07/2025 Non-covered Recipient Entity
PHARMACEUTICAL RESEARCH AND CONSULTING INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211637597
Principal investigator 1 AstraZeneca Pharmaceuticals LP $19,376.71 05/01/2025 Non-covered Recipient Entity
PHARMACEUTICALS RESEARCH CONSULTING INC.
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma No dispute reported 06/30/2026 1185549145
Principal investigator 1 Genentech, Inc. $752.00 04/25/2025 Non-covered Recipient Entity
PHARMACEUTICAL RESEARCH AND CONSULTING INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211637568
Principal investigator 1 Genentech, Inc. $530.00 04/25/2025 Non-covered Recipient Entity
PHARMACEUTICAL RESEARCH AND CONSULTING INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211637572
Principal investigator 1 Genentech, Inc. $1,128.00 04/25/2025 Non-covered Recipient Entity
PHARMACEUTICAL RESEARCH AND CONSULTING INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211637577
Principal investigator 1 Genentech, Inc. $51.00 04/25/2025 Non-covered Recipient Entity
PHARMACEUTICAL RESEARCH AND CONSULTING INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211637584
Principal investigator 1 Genentech, Inc. $180.00 04/25/2025 Non-covered Recipient Entity
PHARMACEUTICAL RESEARCH AND CONSULTING INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211637589
Principal investigator 1 Genentech, Inc. $39.00 04/25/2025 Non-covered Recipient Entity
PHARMACEUTICAL RESEARCH AND CONSULTING INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211637593
Principal investigator 1 Genentech, Inc. $89.70 04/25/2025 Non-covered Recipient Entity
PHARMACEUTICAL RESEARCH AND CONSULTING INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211637601
Principal investigator 1 GlaxoSmithKline, LLC. $6,147.00 04/23/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192175561
Principal investigator 1 AstraZeneca Pharmaceuticals LP $39,359.81 04/15/2025 Non-covered Recipient Entity
PHARMACEUTICALS RESEARCH CONSULTING INC.
a randomized,double blind,multicenter,parallel group,phase IIIb 52 week study evaluating the efficacy and safety of PT027 compared with PT007 administered as needed in participants 12 to under 18 years of age with asthma ACADIA No dispute reported 06/30/2026 1185549151
Principal investigator 1 GlaxoSmithKline, LLC. $8,013.60 02/25/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192175575
Principal investigator 1 AstraZeneca Pharmaceuticals LP $12,312.28 02/20/2025 Non-covered Recipient Entity
PHARMACEUTICALS RESEARCH CONSULTING INC.
a randomized,double blind,multicenter,parallel group,phase IIIb 52 week study evaluating the efficacy and safety of PT027 compared with PT007 administered as needed in participants 12 to under 18 years of age with asthma ACADIA No dispute reported 06/30/2026 1185549153
Principal investigator 1 Genentech, Inc. $3,000.00 02/14/2025 Non-covered Recipient Entity
PHARMACEUTICAL RESEARCH AND CONSULTING INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211637545
Principal investigator 1 Genentech, Inc. $3,259.00 02/14/2025 Non-covered Recipient Entity
PHARMACEUTICAL RESEARCH AND CONSULTING INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211637550
Principal investigator 1 AstraZeneca UK Limited $57,190.45 02/13/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK
a randomized,double blind,multicenter,parallel group,phase IIIb 52 week study evaluating the efficacy and safety of PT027 compared with PT007 administered as needed in participants 12 to under 18 years of age with asthma ACADIA No dispute reported 06/30/2026 1185549135
Principal investigator 1 Genentech, Inc. $371.00 02/05/2025 Non-covered Recipient Entity
PHARMACEUTICAL RESEARCH AND CONSULTING INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211637538
Principal investigator 1 Genentech, Inc. $165.00 02/05/2025 Non-covered Recipient Entity
PHARMACEUTICAL RESEARCH AND CONSULTING INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211637564
Principal investigator 1 AstraZeneca Pharmaceuticals LP $25,712.01 01/31/2025 Non-covered Recipient Entity
PHARMACEUTICALS RESEARCH CONSULTING INC.
A Multicenter Randomized Double Blind Parallel Group Placebo Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients with Severe Chronic Rhinosinusitis with Nasal Polyposis WAYPOINT No dispute reported 06/30/2026 1185549137
Principal investigator 1 GlaxoSmithKline, LLC. $12,865.50 01/24/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192173666
Principal investigator 1 AstraZeneca Pharmaceuticals LP $35,266.62 01/23/2025 Non-covered Recipient Entity
PHARMACEUTICALS RESEARCH CONSULTING INC.
A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma No dispute reported 06/30/2026 1185549133
Principal investigator 1 AstraZeneca Pharmaceuticals LP $546.55 01/23/2025 Non-covered Recipient Entity
PHARMACEUTICALS RESEARCH CONSULTING INC.
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma No dispute reported 06/30/2026 1185549143
Principal investigator 1 AstraZeneca Pharmaceuticals LP $21,427.34 01/22/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma No dispute reported 06/30/2026 1185549149
Principal investigator 1 AstraZeneca Pharmaceuticals LP $148,789.91 01/10/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK
A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma No dispute reported 06/30/2026 1185549139
Principal investigator 1 GlaxoSmithKline, LLC. $215.91 01/08/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192115129
Principal investigator 1 Genentech, Inc. $135.85 01/03/2025 Non-covered Recipient Entity
PHARMACEUTICAL RESEARCH AND CONSULTING INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211637535
Principal investigator 1 Genentech, Inc. $950.00 01/03/2025 Non-covered Recipient Entity
PHARMACEUTICAL RESEARCH AND CONSULTING INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211637542
Principal investigator 1 Genentech, Inc. $452.00 01/03/2025 Non-covered Recipient Entity
PHARMACEUTICAL RESEARCH AND CONSULTING INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211637555
Principal investigator 1 Genentech, Inc. $560.00 01/03/2025 Non-covered Recipient Entity
PHARMACEUTICAL RESEARCH AND CONSULTING INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211637560
Principal investigator 1 Novartis Pharmaceuticals Corporation $112.00 01/01/2025 Non-covered Recipient Entity
PHARMACEUTICAL RESEARCH & CONSULTING INCORPORATION
A 12-week, Multicenter, Randomized, Double-blind, Parallel-arm, Placebo-controlled Study to Assess the Efficacy and Safety of CSJ117, When Added to Existing Asthma Therapy in Patients ? 18 Years of Age With Severe Uncontrolled Asthma. No dispute reported 06/30/2026 1190303491